2026 · 2nd Quarter (Apr 1 - June 30)

FERRING PHARMACEUTICALS, INC.

Filed by FERRING PHARMACEUTICALS, INC..

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 18, 2026
Income: Not reported
Expenses: $250,000.00
Registrant: FERRING PHARMACEUTICALS, INC.
Client: FERRING PHARMACEUTICALS, INC.
Filing UUID: 302822a3-91e6-40c2-bba3-7927d3ad462c
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues related to fertility treatment, oncology and coverage, including: H.R. 8119, the HOPE with Fertility Services Act; H.R. 1670 and S. 797, the Family Building FEHB Fairness Act; H.R. 220, the Veterans Infertility Treatment Act; H.R. 6797, the Bipartisan IVF for Military Families Act; and H.R. 4299, the Protecting Patient Access to Cancer and Complex Therapies Act.

Literal federal measure citations: H.R. 8119, H.R. 1670, S. 797, H.R. 220, H.R. 6797, H.R. 4299

TAX · Taxation/Internal Revenue Code

Issues related to establishing a tax credit for fertility treatments, including: H.R. 1878, the IVF Access and Affordability Act; and H.R. 4639, the Infertility Treatment Affordability Act.

Literal federal measure citations: H.R. 1878, H.R. 4639

TRD · Trade (domestic/foreign)

Issues related to the treatment of pharmaceutical ingredients in trade agreements, including the United States-Argentina Agreement on Reciprocal Trade and Investment.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.